Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254191 | METHODS OF AAV THERAPY | December 2020 | January 2025 | Allow | 49 | 1 | 1 | No | No |
| 17057628 | BIOMARKERS FOR DIAGNOSING TUBERCULOUS MENINGITIS | November 2020 | August 2024 | Allow | 45 | 1 | 1 | No | No |
| 17053148 | COMPOSITIONS AND METHODS FOR CULTURING AND EXPANDING CELLS | November 2020 | April 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17090807 | FURTHER IMPROVED AAV VECTORS PRODUCED IN INSECT CELLS | November 2020 | June 2025 | Allow | 56 | 5 | 1 | No | No |
| 17051578 | IMPROVED BCL11A MICRORNAS FOR TREATING HEMOGLOBINOPATHIES | October 2020 | March 2025 | Allow | 52 | 2 | 1 | No | No |
| 16934573 | MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE | July 2020 | June 2025 | Allow | 59 | 3 | 1 | No | No |
| 16480273 | SYSTEMS AND METHODS FOR IMMUNOMODULATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS | July 2019 | July 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16435710 | METHOD OF EVALUATING NEUTROPHIL ACTIVITY | June 2019 | June 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16432107 | POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY | June 2019 | April 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16463886 | AGENTS FOR THE TREATMENT OF PATIENTS WITH NSCLC AND METHODS TO PREDICT RESPONSE | May 2019 | December 2024 | Abandon | 60 | 1 | 1 | No | No |
| 16415187 | PROTEIN EXPRESSION STRAINS | May 2019 | March 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16305003 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF GENOME-EDITING MOLECULES | November 2018 | January 2025 | Abandon | 60 | 3 | 2 | No | No |
| 16092761 | MASSIVELY MULTIPLEXED HOMOLOGOUS TEMPLATE REPAIR FOR WHOLE-GENOME REPLACEMENT | October 2018 | April 2024 | Abandon | 60 | 4 | 0 | No | No |
| 16144822 | METHODS FOR PROMOTING OLIGODENDROCYTE REGENERATION AND REMYELINATION | September 2018 | December 2024 | Abandon | 60 | 5 | 0 | No | No |
| 16011263 | PLASMA CELL CYTOKINE VEHICLE CONTAINING FUSION PROTEINS FOR TARGETED INTRODUCTION OF SIRNA INTO CELLS AND TISSUES | June 2018 | July 2019 | Allow | 13 | 1 | 1 | No | No |
| 15909666 | METHOD FOR SCREENING INDUCED PLURIPOTENT STEM CELLS | March 2018 | May 2019 | Allow | 14 | 1 | 0 | No | No |
| 15575325 | SCREENING METHODS FOR TARGETS FOR CANCER THERAPY | November 2017 | July 2020 | Abandon | 32 | 8 | 1 | Yes | Yes |
| 15709144 | HOMOLOGOUS RECOMBINATION IN MULTIPOTENT ADULT PROGENITOR CELLS | September 2017 | October 2019 | Allow | 25 | 2 | 0 | No | No |
| 14909713 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | February 2016 | April 2019 | Allow | 39 | 2 | 1 | No | No |
| 14960136 | DNA MOLECULES AND METHODS | December 2015 | September 2019 | Allow | 46 | 4 | 1 | No | No |
| 14655744 | PGC-1beta-Protein-Function Regulator, Mitochondria-Function Regulator, Anti-Obesity Agent, And Screening Method Therefor | August 2015 | May 2017 | Allow | 23 | 1 | 1 | No | No |
| 14669957 | MIXER FOR REMOVING IMPURITIES FROM GASES AND LIQUIDS | March 2015 | June 2015 | Allow | 3 | 0 | 0 | No | No |
| 14415064 | Hypoxia Inducible Factor (HIF) Activity Reporter Cell Line | January 2015 | March 2018 | Allow | 38 | 4 | 1 | No | No |
| 14345745 | miRNA Biomarkers For Ulcerative Colitis | September 2014 | March 2017 | Allow | 36 | 2 | 1 | No | No |
| 14084030 | Gene Cluster for Biosynthesis of Cornexistin and Hydroxycornexistin | November 2013 | June 2017 | Allow | 43 | 3 | 1 | No | No |
| 13944979 | Enrichment of Stem Cells from Adult Tissues | July 2013 | November 2015 | Allow | 27 | 1 | 0 | No | No |
| 13864778 | METHOD FOR DETERMINING THE NEURODEVELOPMENTAL TOXICITY OF A COMPOUND IN VITRO | April 2013 | June 2017 | Allow | 50 | 3 | 0 | No | No |
| 13800478 | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same | March 2013 | June 2014 | Allow | 15 | 1 | 1 | No | No |
| 13572067 | BIOMARKERS OF CANCER METASTASIS | August 2012 | January 2014 | Allow | 17 | 2 | 0 | Yes | No |
| 13476305 | ANF-RGC IN-GENE KNOCK-OUT ANIMAL | May 2012 | June 2014 | Allow | 25 | 4 | 1 | No | No |
| 13454171 | PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME | April 2012 | April 2014 | Allow | 24 | 3 | 0 | Yes | No |
| 13361628 | CELL CULTURE SYSTEM FOR DETERMINING THE SENSITIZING, ALLERGENIC AND/OR IRRITATING EFFECT OF A SUBSTANCE | January 2012 | July 2015 | Allow | 41 | 4 | 0 | No | No |
| 13328785 | BIOMARKER DACT1 FOR GASTRIC CANCER | December 2011 | June 2015 | Allow | 42 | 3 | 1 | Yes | No |
| 13122119 | EXPRESSION VECTOR FOR ESTABLISHING HIGHLY PRODUCTIVE CELL AND THE HIGHLY PRODUCTIVE CELL | March 2011 | June 2013 | Allow | 26 | 1 | 1 | No | No |
| 13025897 | METHODS AND COMPOSITIONS FOR IDENTIFYING INHIBITORS OF MUTS-alpha OR MUTS-beta INTERACTION WITH MUTL-alpha | February 2011 | September 2013 | Allow | 31 | 2 | 1 | No | No |
| 13002502 | METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS | February 2011 | January 2017 | Allow | 60 | 5 | 1 | Yes | Yes |
| 12987601 | TRAP VECTORS AND GENE TRAPPING METHOD BY USING THE SAME | January 2011 | December 2013 | Allow | 35 | 3 | 1 | No | No |
| 12974890 | COMPOSITIONS AND METHODS FOR TRANSFECTION OF RNA AND CONTROLLED STABILIZATION OF TRANSFECTED RNA | December 2010 | July 2013 | Allow | 30 | 2 | 1 | No | No |
| 12746410 | IDENTIFICATION OF TOXIN LIGANDS | September 2010 | July 2013 | Allow | 37 | 2 | 1 | No | No |
| 12842754 | ENRICHMENT OF STEM CELLS FROM ADULT TISSUES | July 2010 | April 2013 | Allow | 32 | 2 | 1 | No | No |
| 12778938 | INTEGRATION-FREE HUMAN INDUCED PLURIPOTENT STEM CELLS FROM BLOOD | May 2010 | August 2011 | Allow | 15 | 2 | 0 | Yes | No |
| 12726099 | RECOMBINANT CONSTRUCT FOR DETECTION OF HALOGENATED AROMATIC HYDROCARBONS | March 2010 | April 2012 | Allow | 25 | 2 | 1 | No | No |
| 12450939 | CONSTRUCTS FOR ENHANCEMENT OF GENE EXPRESSION IN MUSCLE | March 2010 | August 2015 | Allow | 60 | 4 | 0 | No | No |
| 12714257 | SCDs As Modifiers of the p53 Pathway and Methods of Use | February 2010 | March 2014 | Allow | 49 | 3 | 0 | No | No |
| 12706683 | BIDIRECTIONAL PROMOTERS IN NANNOCHLOROPSIS | February 2010 | July 2012 | Allow | 29 | 2 | 1 | No | No |
| 12699180 | COMPOSITIONS AND METHODS FOR REGULATING RNA TRANSLATION VIA CD154 CA-DINUCLEOTIDE REPEAT | February 2010 | June 2012 | Allow | 29 | 2 | 1 | No | No |
| 12693167 | SYSTEM AND METHOD FOR IDENTIFYING ERYTHROPOIETIN-RESPONSIVE GENES | January 2010 | September 2012 | Allow | 32 | 3 | 0 | No | No |
| 12643149 | METHODS FOR THE PREPARATION OF FIBROBLASTS | December 2009 | February 2015 | Allow | 60 | 3 | 1 | No | No |
| 12457200 | Promoters exhibiting endothelial cell specificity and methods of using same | June 2009 | March 2014 | Allow | 58 | 4 | 1 | Yes | No |
| 12410748 | PCRYPTORNAI | March 2009 | January 2012 | Allow | 33 | 2 | 0 | Yes | No |
| 12441806 | Facs- and Reporter Protein-Based System for High Throughput Development of Therapeutic Proteins | March 2009 | March 2025 | Abandon | 60 | 16 | 1 | Yes | Yes |
| 12374472 | ASSAY AND KIT FOR PREDICTING IMPLANTATION SUCCESS IN ASSISTED FERTILISATION | January 2009 | March 2012 | Allow | 37 | 1 | 1 | Yes | No |
| 12338728 | sVEGFR-2 AND ITS ROLE IN LYMPHANGIOGENESIS MODULATION | December 2008 | May 2014 | Allow | 60 | 2 | 1 | No | No |
| 12316581 | COMPOSITIONS AND METHODS RELATED TO MRNA TRANSLATIONAL ENHANCER ELEMENTS | December 2008 | August 2012 | Allow | 45 | 2 | 2 | No | No |
| 11573035 | PROCESS AND GENES FOR EXPRESSION AND OVEREXPRESSION OF ACTIVE [FeFe] HYDROGENASES | November 2008 | April 2014 | Allow | 60 | 2 | 1 | No | No |
| 12263272 | IMMUNOGLOBULIN DISPLAY VECTORS | October 2008 | January 2011 | Allow | 27 | 1 | 1 | No | No |
| 12225355 | EXPRESSION AUGMENTING DNA FRAGMENTS, USE THEREOF, AND METHODS FOR FINDING THEREOF | September 2008 | April 2011 | Allow | 30 | 2 | 1 | Yes | No |
| 12233836 | RECOMBINATIONAL CLONING USING NUCLEIC ACIDS HAVING RECOMBINATION SITES | September 2008 | February 2010 | Allow | 16 | 1 | 0 | No | No |
| 12195647 | PROMOTER FOR INTRODUCING A GENE INTO A LYMPHOCYTE OR BLOOD CELL AND APPLICATION THEREOF | August 2008 | May 2011 | Allow | 33 | 2 | 1 | Yes | No |
| 12195665 | PROMOTER FOR INTRODUCING A GENE INTO A LYMPHOCYTE OR BLOOD CELL AND APPLICATION THEREOF | August 2008 | May 2011 | Allow | 33 | 2 | 1 | Yes | No |
| 10574333 | COMPOSITIONS AND METHODS FOR GENE EXPRESSION | July 2008 | March 2012 | Allow | 60 | 3 | 1 | Yes | No |
| 12161677 | METHOD OF IMPROVING CELL PROLIFERATION OF PANCREATIC PROGENITOR CELLS IN A PANCREATIC CELL CULTURE | July 2008 | April 2017 | Allow | 60 | 5 | 1 | No | No |
| 11991637 | PROMOTER FOR INTRODUCING A GENE INTO A LYMPHOCYTE OR BLOOD CELL AND APPLICATION THEREOF | July 2008 | April 2011 | Allow | 37 | 3 | 0 | Yes | No |
| 12156936 | COMBINATORIAL DNA LIBRARY FOR PRODUCING MODIFIED N-GLYCANS IN LOWER EUKARYOTES | June 2008 | June 2010 | Allow | 24 | 1 | 0 | No | No |
| 12057014 | PSEUDO-TISSUE FOR ACCURACY CONTROL, METHOD FOR CONTROLLING ACCURACY BY USING THE SAME, AND METHOD FOR MANUFACTURING THE SAME | March 2008 | March 2015 | Allow | 60 | 4 | 1 | No | No |
| 12052268 | USE OF THERAPEUTICALLY EFFECTIVE LIPIDS AND METHOD FOR PRODUCING ORGAN-/TISSUE-SPECIFIC THERAPEUTICALLY EFFECTIVE LIPIDS | March 2008 | July 2014 | Allow | 60 | 4 | 1 | No | No |
| 12052674 | AMBULATORY PATIENT MONITORING APPARATUS, SYSTEM AND METHOD | March 2008 | September 2014 | Allow | 60 | 2 | 1 | Yes | No |
| 12048599 | MULTIPLE PROMOTERS AND THE USE THEREOF FOR GENE EXPRESSION | March 2008 | February 2011 | Allow | 35 | 2 | 0 | Yes | No |
| 12037117 | EXPRESSION VECTOR, A TRANSFORMANT CARRYING THE SAME AND A METHOD FOR PRODUCING HETEROLOGOUS PROTEIN | February 2008 | April 2010 | Allow | 25 | 1 | 0 | No | No |
| 12036722 | BIASING OF CELLS TOWARD RETINAL, CORNEAL OR LENS DEVELOPMENT | February 2008 | September 2015 | Allow | 60 | 8 | 1 | Yes | Yes |
| 11995398 | REPORTER VECTOR FOR USE IN EVALUATION OF CYP1A2 INDUCTION | February 2008 | November 2010 | Allow | 34 | 2 | 0 | No | No |
| 11949306 | MODULATORS OF THE ORPHAN G PROTEIN-COUPLED RECEPTORS GPR78 AND GPR26 | December 2007 | September 2010 | Allow | 34 | 1 | 1 | No | No |
| 11926203 | METHYL-CPG ISLAND-ASSOCIATED GENOME SIGNATURE TAGS | October 2007 | March 2014 | Allow | 60 | 3 | 1 | No | No |
| 11874838 | JAB1 AS A PROGNOSTIC MARKER AND A THERAPEUTIC TARGET FOR HUMAN CANCER | October 2007 | December 2013 | Allow | 60 | 2 | 0 | No | Yes |
| 11840903 | IDENTIFICATION OF GENES | August 2007 | June 2010 | Allow | 34 | 2 | 1 | No | No |
| 11890842 | Epididymal lipocalin gene and uses thereof | August 2007 | July 2013 | Allow | 60 | 2 | 1 | Yes | No |
| 11801641 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | May 2007 | December 2010 | Allow | 43 | 2 | 1 | No | No |
| 11726388 | TELOMERASE EXPRESSION REPRESSOR PROTEINS AND METHODS OF USING THE SAME | March 2007 | April 2010 | Allow | 37 | 2 | 0 | No | No |
| 11578476 | Transgenomic Mitochondria, Transmitochondrial Cells and Organisms, and Methods of Making and Using | October 2006 | January 2013 | Allow | 60 | 5 | 1 | No | No |
| 11494363 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS | July 2006 | December 2009 | Allow | 41 | 3 | 1 | Yes | No |
| 10585149 | Transactivation system for mammalian cells | June 2006 | October 2012 | Allow | 60 | 4 | 1 | No | No |
| 10933874 | MULTI-ANTIGEN VECTORS OF MELANOMA | September 2004 | August 2009 | Abandon | 59 | 4 | 1 | No | No |
| 10893235 | RECOMBINATIONAL CLONING USING NUCLEIC ACIDS HAVING RECOMBINATION SITES | July 2004 | March 2008 | Allow | 48 | 1 | 2 | No | No |
| 10858271 | COMPOSITIONS AND METHODS FOR SENSITIZING AND INHIBITING GROWTH OF HUMAN TUMOR CELLS | June 2004 | September 2008 | Allow | 52 | 3 | 2 | No | No |
| 10806515 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MALE ERECTILE DYSFUNCTION | March 2004 | August 2008 | Allow | 53 | 2 | 1 | No | No |
| 10741509 | CHOLESTEROL REDUCTION SIGNATURE | December 2003 | July 2008 | Allow | 55 | 3 | 1 | No | No |
| 10731739 | HIGH BONE MASS GENE OF 11Q13.3 | December 2003 | June 2007 | Allow | 43 | 2 | 1 | No | No |
| 10702319 | COMPOSITIONS AND METHODS FOR THE MODIFICATION OF GENE EXPRESSION | November 2003 | December 2010 | Allow | 60 | 6 | 1 | Yes | Yes |
| 10696708 | MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT SYNDROME GENE | October 2003 | June 2007 | Allow | 44 | 2 | 0 | No | No |
| 10467104 | METHODS AND KITS FOR IDENTIFYING SCAVENGERS OF REACTIVE OXYGEN SPECIES (ROS) | August 2003 | February 2008 | Allow | 54 | 6 | 0 | Yes | Yes |
| 10603387 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS | June 2003 | April 2006 | Allow | 34 | 1 | 1 | No | No |
| 10457604 | MUTATED HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASES AND USES THEREOF | June 2003 | August 2005 | Allow | 26 | 1 | 0 | No | No |
| 10239595 | ESTABLISHMENT OF CELLULAR MANIPULATIONS WHICH ENHANCE OLIGO-MEDIATED GENE TARGETING | March 2003 | September 2007 | Allow | 60 | 3 | 0 | Yes | No |
| 10371877 | COMBINATORIAL DNA LIBRARY FOR PRODUCING MODIFIED N-GLYCANS IN LOWER EUKARYOTES | February 2003 | February 2008 | Allow | 60 | 3 | 1 | No | No |
| 10204884 | CORNEODESMOSIN BASED TEST AND MODEL FOR INFLAMMATORY DISEASE | January 2003 | August 2007 | Allow | 60 | 2 | 1 | Yes | Yes |
| 10347718 | MAMMARY GLAND TISSUE-SPECIFIC EXPRESSION SYSTEM USING BETA-CASEIN PROMOTER SITE OF KOREAN NATIVE GOAT | January 2003 | December 2005 | Allow | 35 | 1 | 1 | No | No |
| 10338691 | ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF | January 2003 | December 2004 | Allow | 23 | 0 | 1 | No | No |
| 10336091 | UPSTREAM CONTROL ELEMENTS OF THE PROOPIOMELANOCORTIN GENE AND THEIR USE | January 2003 | May 2006 | Allow | 40 | 2 | 1 | No | No |
| 10319564 | ADULT T CELL LEUKEMIA MODEL ANIMAL | December 2002 | May 2006 | Allow | 41 | 1 | 0 | No | No |
| 10181545 | MYOSTATIN AND MIMETICS THEREOF | November 2002 | September 2007 | Allow | 60 | 5 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner QIAN, CELINE X.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner QIAN, CELINE X works in Art Unit 1637 and has examined 143 patent applications in our dataset. With an allowance rate of 92.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner QIAN, CELINE X's allowance rate of 92.3% places them in the 78% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by QIAN, CELINE X receive 2.69 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by QIAN, CELINE X is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -4.6% benefit to allowance rate for applications examined by QIAN, CELINE X. This interview benefit is in the 7% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 25.4% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 51.4% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 43% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 92.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 76.6% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 15.4% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.0% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.